MG billed itself as “the sports car that America loved first ... Run of 6682 North American Limited Editions starts. 1980: 17 character VIN and 80 mph speedometer. Final cars produced in October of ...

compresse di Aristos P 20 mg: 1; compresse di Aristos P 80 mg: ¼ Peso dell'animale: 12-17 kg; compresse di Aristos P 10 mg: 3; compresse di Aristos P 20 mg: 1+½ Peso dell'animale: 17-25 kg; compresse ...

I pazienti affetti da rari problemi ereditari di intolleranza al galattosio, da deficit totale di lattasi, o da malassorbimento di glucosio-galattosio, non devono assumere questo medicinale. Gli studi ...

All in all, Ingrezza pulled in $2.3 billion in 2024, making for an “all-time record growth year” for the drug, Benevich noted. Teva's Austedo, meanwhile, collected $1.6 billion in sales last year.

Neurocrine Biosciences Q4 EPS of $1.69 beat estimates, while revenue missed consensus. Ingrezza sales rose 23% to $615 million. 2025 Ingrezza sales guidance fell short of Street estimate.

He emphasized the strong performance of INGREZZA, which is poised for double-digit year-over-year growth despite moderated expectations compared to 2024, the company’s highest growth year to date.

INGREZZA Sales Guidance for 2025: $2.5 billion to $2.6 billion, reflecting $250 million growth at the midpoint. CRENESSITY Q4 2024 Sales: $2 million in net sales from initial bottle orders.

On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a year ago, beating the consensus of $1.56. The company ...

From a commercial perspective, INGREZZA continues to set the standard. Eight years after introducing the first treatment for tardive dyskinesia, we're on track to once again achieve double-digit ...

According to reports, Verma cited uninspiring guidance for the company's leading drug, Ingrezza (a treatment for movement disorder tardive dyskinesia). Management proffered guidance for Ingrezza ...

FY25 revenue consensus $2.79B. Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock ...

The new ETFs' attractive initial cap rates complement the already launched 100% (CBOJ) protection ETF, providing investors with a combination of protection levels and upside potential unavailable ...